Head and Neck Cancer
- Lip, Oral Cavity and Pharynx, LarynxThe BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPrincipal Investigator: Aarti Bhatia
- Larynx, Lip, Oral Cavity and PharynxA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk FeaturesPrincipal Investigator: Aarti Bhatia
- Larynx, Lip, Oral Cavity and PharynxA Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)Principal Investigator: Barbara Burtness
- Corpus Uteri, Larynx, Lung, Soft Tissue, Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid TumorsPrincipal Investigator: Alessandro Santin
- Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Thyroid, Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Principal Investigator: Barbara Burtness